Canine and Feline Electrocardiography
... • SA node is the primary pacemaker of the heart, but any cells of conduction system can initiate their own impulses under right circumstances • The further down in the conduction system, the slower the rate of automaticity • 2. Excitability • Cardiac muscle is excited when the electrical stimulus re ...
... • SA node is the primary pacemaker of the heart, but any cells of conduction system can initiate their own impulses under right circumstances • The further down in the conduction system, the slower the rate of automaticity • 2. Excitability • Cardiac muscle is excited when the electrical stimulus re ...
Cardiac Cycle and Intrinsic Beat - Mr. Lesiuk
... - The SA Node (also called the pacemaker) initiates the heartbeat and sends out an excitation impulses every 0.85 seconds. The impulse causes both Atria to contract. - When the impulse reaches the AV Node, an impulse is sent from the AV Node, down the "Bundles of His" and onto the Purkinje Fibers ca ...
... - The SA Node (also called the pacemaker) initiates the heartbeat and sends out an excitation impulses every 0.85 seconds. The impulse causes both Atria to contract. - When the impulse reaches the AV Node, an impulse is sent from the AV Node, down the "Bundles of His" and onto the Purkinje Fibers ca ...
Feline Cardiac Support - Veterinary Center of Parker Inc.
... Feline Cardiac Support is a nutritional supplement formulated with ingredients known as functional foods. These are foods that have been shown to benefit various organs and tissues in the body. Feline Cardiac Support is formulated to provide support for the myriad of tissues involved in cardiovascul ...
... Feline Cardiac Support is a nutritional supplement formulated with ingredients known as functional foods. These are foods that have been shown to benefit various organs and tissues in the body. Feline Cardiac Support is formulated to provide support for the myriad of tissues involved in cardiovascul ...
What is Dilated Cardiomyopathy (DCM
... Dilated Cardiomyopathy is a disease of the heart muscle which causes the muscle wall to become weaker. This means that the heart is unable to pump effectively, and so more blood remains in the heart chambers causing them to become enlarged, or dilated. Eventually the heart will go into failure. Are ...
... Dilated Cardiomyopathy is a disease of the heart muscle which causes the muscle wall to become weaker. This means that the heart is unable to pump effectively, and so more blood remains in the heart chambers causing them to become enlarged, or dilated. Eventually the heart will go into failure. Are ...
Running head: CURRENT RESEARCH AND TREATMENT FOR AF
... Running head: CURRENT RESEARCH AND TREATMENT FOR AF ...
... Running head: CURRENT RESEARCH AND TREATMENT FOR AF ...
MANAGING SUDDEN CARDIAC DEATH RISK IN NEWLY
... Figure 1: EKG downloaded from WCD. The WCD continuously monitors the patient’s EKG using a 4 electrode, 2 lead system—side-to-side (SS, top) and front-to-back (FB, bottom). ...
... Figure 1: EKG downloaded from WCD. The WCD continuously monitors the patient’s EKG using a 4 electrode, 2 lead system—side-to-side (SS, top) and front-to-back (FB, bottom). ...
A Guide to the Etiology, Pathophysiology, Diagnosis, and
... Beta-Blockers • Cardioprotective effects due to blockade of excessive SNS stimulation • In the short-term, beta blocker decreases myocardial contractility; increase in EF after 1-3 months of use • Long-term, placebo-controlled trials have shown symptomatic improvement in patients treated with certai ...
... Beta-Blockers • Cardioprotective effects due to blockade of excessive SNS stimulation • In the short-term, beta blocker decreases myocardial contractility; increase in EF after 1-3 months of use • Long-term, placebo-controlled trials have shown symptomatic improvement in patients treated with certai ...
Exam 2 Review Essay KEY
... Remove SA node – AV node takes over, ectopic focus, heart rate around 40-60 bpm Remove AV node – ventricles will not contract, not compatible with life ...
... Remove SA node – AV node takes over, ectopic focus, heart rate around 40-60 bpm Remove AV node – ventricles will not contract, not compatible with life ...
Atrial fibrillation
... It should be noted that in otherwise healthy patients under 55 years (CHAD 2 score 0, see appendix 1 below), this is commonly not done. It may be reasonable to also discharge the patient home on aspirin 325 mg daily (or clopidogrel if the patient is unable to take this) until specialist cardiologist ...
... It should be noted that in otherwise healthy patients under 55 years (CHAD 2 score 0, see appendix 1 below), this is commonly not done. It may be reasonable to also discharge the patient home on aspirin 325 mg daily (or clopidogrel if the patient is unable to take this) until specialist cardiologist ...
Template for BMJ Cases - ELSO 2016
... DBT 10 ug/kg/min and cold ischemia time of 4h 15 min (optimal <3 h) that may have contributed to the origin of PGF. Although there are case reports of heart transplant patients who received Central VAECMO implant due to failure of weaning from BCP (3,4), no one reported any case showing so long supp ...
... DBT 10 ug/kg/min and cold ischemia time of 4h 15 min (optimal <3 h) that may have contributed to the origin of PGF. Although there are case reports of heart transplant patients who received Central VAECMO implant due to failure of weaning from BCP (3,4), no one reported any case showing so long supp ...
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naı¨ve atrial fibrillation patients
... trials remains limited, and further insights into appropriate use will undoubtedly become apparent as these agents are prescribed ...
... trials remains limited, and further insights into appropriate use will undoubtedly become apparent as these agents are prescribed ...
CardiovascularReport - Johns Hopkins Medicine
... Atrial Fibrillation: Saying Goodbye to Blood Thinners (continued from page 1) previous cardiac surgery, due to scar tissue that can hinder implantation. The third device, the LARIAT, is a catheter-implanted suture delivery loop that ties off the LAA. Although this procedure also doesn’t require post ...
... Atrial Fibrillation: Saying Goodbye to Blood Thinners (continued from page 1) previous cardiac surgery, due to scar tissue that can hinder implantation. The third device, the LARIAT, is a catheter-implanted suture delivery loop that ties off the LAA. Although this procedure also doesn’t require post ...
Name - Wilson`s Web Page
... ___ 1. Explain why the side of the heart on your left in diagrams is called the right side. ___ 2. What is meant by myocardium? ___ 3. What is the function of the Septum? ____4 . Name the four chambers in the order that blood would travel through them, starting from the vena cavas. ___ 5. What name ...
... ___ 1. Explain why the side of the heart on your left in diagrams is called the right side. ___ 2. What is meant by myocardium? ___ 3. What is the function of the Septum? ____4 . Name the four chambers in the order that blood would travel through them, starting from the vena cavas. ___ 5. What name ...
Pharmacotherapy of Cardiogenic Shock_Master
... o MI can cause SIRS, which results in low-normal SVRs (inappropriate vasodilation) - Do not rely on the BP to tell you if a patient is in shock! o In animal studies, MAP < 60 has been shown to be detrimental to cellular processes o Patients with HTN may require a higher MAP to maintain tissue perfus ...
... o MI can cause SIRS, which results in low-normal SVRs (inappropriate vasodilation) - Do not rely on the BP to tell you if a patient is in shock! o In animal studies, MAP < 60 has been shown to be detrimental to cellular processes o Patients with HTN may require a higher MAP to maintain tissue perfus ...
Gabriel Cassalett MD Pediatric Intensivist Clínica Shaio Bogotá
... A wide (a-v)O2 difference usually reflects a low cardiac output and large oxygen extraction A narrow (a-v)O2 difference usually reflects the ...
... A wide (a-v)O2 difference usually reflects a low cardiac output and large oxygen extraction A narrow (a-v)O2 difference usually reflects the ...
Cardiac Rhythm Management
... CRT-P Systems from Boston Scientific CRM – INVIVE Indications The Invive cardiac resynchronization therapy pacemaker (CRT-Ps) is indicated for patients who have moderate to severe heart failure (NYHA Class III/IV) including left ventricular dysfunction (EF ≤ 35%) and QRS duration ≥ 120 ms and remain ...
... CRT-P Systems from Boston Scientific CRM – INVIVE Indications The Invive cardiac resynchronization therapy pacemaker (CRT-Ps) is indicated for patients who have moderate to severe heart failure (NYHA Class III/IV) including left ventricular dysfunction (EF ≤ 35%) and QRS duration ≥ 120 ms and remain ...
paroxysmal supraventricular tachycardia in the rural
... In a small number of patients—those with Wolff-ParkinsonWhite syndrome, in which preexcitation is evident on the electroccardiogram—there is a small but significant risk of cardiac arrest during their tachycardia. Cardiac arrest is due to rapid conduction of atrial fibrillation over the accessory co ...
... In a small number of patients—those with Wolff-ParkinsonWhite syndrome, in which preexcitation is evident on the electroccardiogram—there is a small but significant risk of cardiac arrest during their tachycardia. Cardiac arrest is due to rapid conduction of atrial fibrillation over the accessory co ...
TECHNICAL CORNER - American Association of Sleep Technologists
... with mild and severe disease. This manifests as either central, mixed or obstructive sleep apnea/hypopnea. Sleep disordered breathing contributes to a poorer prognosis in CHF patients although it is rarely associated with daytime sleepiness.2 Therefore, it is important for sleep technologists to be ...
... with mild and severe disease. This manifests as either central, mixed or obstructive sleep apnea/hypopnea. Sleep disordered breathing contributes to a poorer prognosis in CHF patients although it is rarely associated with daytime sleepiness.2 Therefore, it is important for sleep technologists to be ...
ICD FOR PRIMARY PREVENTION
... death from any cause in the subgroup with ischemic CMPY (HR for death, 0.73; 95% C.I, 0.52 to 1.04) & a 50 ...
... death from any cause in the subgroup with ischemic CMPY (HR for death, 0.73; 95% C.I, 0.52 to 1.04) & a 50 ...
File
... Describe the substance normally found in the pericardial cavity. Describe the movement of the atria during contraction. …the ventricles. Describe the tissue construction of each of the three layers of the heart wall. How are endocardium and endothelium related? ...
... Describe the substance normally found in the pericardial cavity. Describe the movement of the atria during contraction. …the ventricles. Describe the tissue construction of each of the three layers of the heart wall. How are endocardium and endothelium related? ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.